Bonus Content - Accredited Activities

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 1 of the activity, including how MCED testing is helping to address the cancer screening gap in the US and the importance of staying up to date on developments in MCED testing. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. 

Click here to claim your CME credit: https://bit.ly/3X8apxa

Additional Advances in MCED Technologies: The Impact of MCED Testing + Module 1 Activity

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 2 of the activity, including the value of MCED testing for cancer survivors and ongoing trials investigating MCEDs that he’s looking forward to seeing results of in the near future. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. 

Click here to claim your CME credit: https://bit.ly/41rS14I

Additional Advances in MCED Technologies: Cancer Survivorship and Emerging Trials + Module 2 Activity

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 3 of the activity, including questions he commonly gets from patients about MCED testing and advice for clinicians about employing shared decision making with patients to choose the most appropriate type of cancer screening for them. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. 

Click here to claim your CME credit: https://bit.ly/4b9JU00

Additional Advances in MCED Technologies: MCED Testing and Shared Decision Making + Module 3 Activity

As we recognize Kidney Cancer Awareness Month this March, advancements in renal cell carcinoma (RCC) treatment continue to evolve. Recently, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, a Nurse Practitioner and expert in genitourinary oncology, chaired the i3 Health’s NCPD activity titled Toxicity Management and Symptom Control in Advanced RCC: Playbook Update. In this interview, she shares updates in RCC treatment, strategies for toxicity management, and the importance of patient education.

Click here for the full NCPD activity! https://i3health.com/course-information/toxicity-management-and-symptom-control-in-advanced-rcc-playbook-update

Additional Advances in Renal Cell Carcinoma Research and Clinical Trials With Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month.   



Click the link for the full activity! https://bit.ly/4hyVwLn

Additional Advances in Stem Cell Mobilization Research and Clinical Trials in Multiple Myeloma With Hamza Hashmi, MD

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education. 

Click the links below for the full CME activity!

Module 1: https://bit.ly/3X8apxa
Module 2 : https://bit.ly/41rS14I
Module 3: https://bit.ly/4b9JU00


And view the slide decks here:

Module 1: https://bit.ly/4l0NTzc
Module 2: https://bit.ly/4fdXwti
Module 3: https://bit.ly/40AkmoP

Multicancer Early Detection: A Fellow’s Perspective With Waqas Haque, MD, MPH

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education.

Click the links below for the full CME activity!

Module 1: bit.ly/3X8apxa
Module 2 : bit.ly/41rS14I
Module 3: bit.ly/4b9JU00

And view the slide decks here:

Module 1: bit.ly/4l0NTzc
Module 2: bit.ly/4fdXwti
Module 3: bit.ly/40AkmoP

oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM.

In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration.

Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!

Register Here: bit.ly/3UgV7nF

Unmasking Hereditary ATTR-CM: A Webinar Preview With Mathew Maurer, MD

For patients with ulcerative colitis, newly developed therapies and tailored treatment strategies have allowed for a more personalized approach to achieving disease control and remission. In this special podcast interview, Dr. Benjamin Cohen, Co-Section Head and Clinical Director of Inflammatory Bowel Diseases at the Cleveland Clinic, offers a behind-the-scenes look at i3 Health’s Virtual Escape Room, which follows Shawn, a 32-year-old man living with ulcerative colitis. Dr. Cohen discusses the greatest challenges in diagnosis and treatment, the importance of staying current with novel therapies and biomarkers, and how this engaging, gamified format not only enhances learning but also translates to improved patient outcomes.
Click here to complete the escape room and claim free CME credit!
https://i3Health.com/uc-escape

Solving the Ulcerative Colitis Puzzle: How to Navigate the Treatment Journey

Don’t miss your chance—listen to Module 1 and claim your CME credit by August 19! 

Join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge field of multicancer early detection (MCED). In this engaging session, Dr. Vega delves into the scientific foundations of blood-based cancer screening, examining both current limitations and the exciting promise of MCED technologies. Discover how these innovative tests use biomarkers to detect multiple cancers in a single, convenient screening—offering a breakthrough solution to challenges like low awareness and limited access to screening facilities. 

Remember, you have only until August 19 to listen and earn your CME credit!

Click here to claim your credit: bit.ly/3X8apxa
Click here to download the slide deck: bit.ly/4l0NTzc

EXPIRING SOON! Optimizing Cancer Screening With MCED Technologies - Module 1: Science Behind Cancer Screening

Time is running out—listen to Module 2 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In Module 2, Dr. Charles Vega takes you deeper into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, early detection is more important than ever. Dr. Vega reviews the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, and explores how these advances could revolutionize cancer screening and improve patient outcomes. 

Don’t forget—you must listen and claim your CME credit by August 19!

Click here to claim your credit: bit.ly/41rS14I
Click here to download the slide deck: bit.ly/4fdXwti

EXPIRING SOON! Optimizing Cancer Screening With MCED Technologies - Module 2: Clinical Evidence for MCED Testing

Hurry—listen to Module 3 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In this final module, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, explores the practical implementation of multicancer early detection (MCED) tests in clinical practice. Gain valuable insights into how these groundbreaking innovations could transform cancer screening and improve patient outcomes. 

Remember, you have only until August 19 to listen and claim your CME credit!

Click here to claim your credit: bit.ly/4b9JU00
Click here to download the slide deck: bit.ly/40AkmoP

EXPIRING SOON! Optimizing Cancer Screening With MCED Technologies - Module 3: Implementing MCED Testing in Clinical Practice Through Case Studies

Don’t miss your chance—listen to Module 1 and claim your CME credit by August 19!

Join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge field of multicancer early detection (MCED). In this engaging session, Dr. Vega delves into the scientific foundations of blood-based cancer screening, examining both current limitations and the exciting promise of MCED technologies. Discover how these innovative tests use biomarkers to detect multiple cancers in a single, convenient screening—offering a breakthrough solution to challenges like low awareness and limited access to screening facilities.

Remember, you have only until August 19 to listen and earn your CME credit!

Click here to claim your credit: bit.ly/3X8apxa
Click here to download the slide deck: bit.ly/4l0NTzc

Time is running out—listen to Module 2 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In Module 2, Dr. Charles Vega takes you deeper into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, early detection is more important than ever. Dr. Vega reviews the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, and explores how these advances could revolutionize cancer screening and improve patient outcomes.

Don’t forget—you must listen and claim your CME credit by August 19!

Click here to claim your credit: bit.ly/41rS14I
Click here to download the slide deck: bit.ly/4fdXwti

Hurry—listen to Module 3 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In this final module, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, explores the practical implementation of multicancer early detection (MCED) tests in clinical practice. Gain valuable insights into how these groundbreaking innovations could transform cancer screening and improve patient outcomes.

Remember, you have only until August 19 to listen and claim your CME credit!

Click here to claim your credit: bit.ly/4b9JU00
Click here to download the slide deck: bit.ly/40AkmoP

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Multicancer Early Detection: A Fellow’s Perspective With Waqas Haque, MD, MPH

Oncology Data Advisor®

Related tracks